scholarly journals Rhodomyrtone as a New Natural Antibiotic Isolated from Rhodomyrtus tomentosa Leaf Extract: A Clinical Application in the Management of Acne Vulgaris

Antibiotics ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 108
Author(s):  
Suttiwan Wunnoo ◽  
Siwaporn Bilhman ◽  
Thanaporn Amnuaikit ◽  
Julalak C. Ontong ◽  
Sudarshan Singh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Clinical Assessment ◽  
Leaf Extract ◽  
Acne Vulgaris ◽  
Treated Group ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Treatment Groups ◽  
Rhodomyrtus Tomentosa

Rhodomyrtone, a plant-derived principal compound isolated from Rhodomyrtus tomentosa (Myrtaceae) leaf extract, was assessed as a potential natural alternative for the treatment of acne vulgaris. The clinical efficacy of a 1% liposomal encapsulated rhodomyrtone serum was compared with a marketed 1% clindamycin gel. In a randomized and double-blind controlled clinical trial, 60 volunteers with mild to moderate acne severity were assigned to two groups: rhodomyrtone serum and clindamycin gel. The volunteers were instructed to apply the samples to acne lesions on their faces twice daily. A significant reduction in the total numbers of acne lesions was demonstrated in both treatment groups between week 2 and 8 (p < 0.05). Significant differences in acne numbers compared with the baseline were evidenced at week 2 onwards (p < 0.05). At the end of the clinical trial, the total inflamed acne counts in the 1% rhodomyrtone serum group were significantly reduced by 36.36%, comparable to 34.70% in the clindamycin-treated group (p < 0.05). Furthermore, a commercial prototype was developed, and a clinical assessment of 45 volunteers was performed. After application of the commercial prototype for 1 week, 68.89% and 28.89% of volunteers demonstrated complete and improved inflammatory acne, respectively. All of the subjects presented no signs of irritation or side effects during the treatment. Most of the volunteers (71.11%) indicated that they were very satisfied. Rhodomyrtone serum was demonstrated to be effective and safe for the treatment of inflammatory acne lesions.

scholarly journals The effect of blue and pink lotus flower extract on acne vulgaris: A randomized double-blind clinical trial

2021 ◽  
Author(s):  
Anna Gordon
Keyword(s):  
Clinical Trial ◽  
Treatment Group ◽  
Side Effect ◽  
Acne Vulgaris ◽  
Treated Group ◽  
Small Sample ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Flower Extract ◽  
Lotus Flower

Background:Acne vulgaris is one of the leading ubiquitous diseases around the world. It is a multifactorial diseasewhich does not threaten life but has serious psychological effects on patients. Patients with moderate tosevere acne have been suggested to have poor body image, poor self-esteem, and social isolation andactivity constraints. Increased levels of anxiety, anger, depression and frustration are also observed inpatients with acne as part of the emotional impact.Research gap:More research on anti-acne treatments is necessary for two reasons. First, the prevalence of acneincidence is high and the effect on the quality of life is profound. Second, there is, according to thenumerous studies, a lack of ant-acne treatments that have less side effect. The use of medicinal plantsand particularly blue and pink lotus flower extract, with its autoinflammatory effect, could bepromising. The blue and pink lotus flower extract is suggested to reduces the activity of sebumoverproduction and helps to balance sebum secretion.Objective:The objective of this study was to examine the medical efficacy of blue and pink lotus flower extract inacne vulgaris.Method:In a randomized double-blind controlled clinical trial, 42 patients (21 patients in treatment and 21 inplacebo group) were randomly received ‘’Nymphaea Caerulea Flower Extract, Nelumbo NuciferaFlower’’ and placebo extract, twice daily for 1 month. We recorded he Investigator's GlobalAssessment (IGA) grading score for each participant. In addition, we evaluated the Acne disabilityindex (ADI) utilizing a standard questionnaire filled out by the participants at the beginning and at theend of the study.Results:The results indicated a 76% mean reduction in the IGA score on the treated group. The mean reductionin the vehicle-treated group, on the other hand, was 4.2%. We also found that the number of comedones,papules, and pustules significantly reduced in the treatment group after 30 days. Additionally, the Acnedisability index (ADI) score decreased by 65.01 percent in treatment group, and only 5.6 percent in theplacebo group. The current study could not discover any significant side effect in both groups.Conclusion:The blue and pink lotus flower extract had significant effects on improving the symptoms of acnevulgaris. The results of this study, because of the small sample size, should however be interpreted withcaution. The future study on the medical efficacy of the mentioned extract should examine with largersamples.

Rosa Damascena Improved Sexual Dysfunction in Males Under Methadone Treatment – Results from a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

2017 ◽  
Vol 41 (S1) ◽  
pp. S281-S281
Author(s):  
V. Farnia ◽  
F. Tatari ◽  
M. Alikhani ◽  
J. Shakeri ◽  
M. Taghizadeh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Methadone Treatment ◽  
Controlled Clinical Trial ◽  
Rosa Damascena ◽  
Placebo Condition ◽  
Double Blind ◽  
Male Patients ◽  
Competing Interest

IntroductionPatients with severe opioid dependency might be treated with methadone, a pure μ-opioid-receptor, with promising results. Though, as for opioids, side effects are high, and among those, sexual dysfunction is among the most disturbing side effects.AimsInvestigating the influence of Rosa Damascena oil to improve sexual dysfunction among male methadone users.MethodsA total of 60 male patients (mean age: 30 years) with diagnosed opioid dependence and currently under treatment of methadone were randomly assigned either to the verum (Rosa Damascenca oil drops) or placebo condition. At baseline, and four and eight weeks later, patients completed self-rating questionnaires covering sexual dysfunction and happiness.ResultsOver time sexual dysfunction decreased and happiness increased in the verum, but not in the placebo condition.ConclusionsResults from this double blind, randomized, and placebo-controlled clinical trial showed that Rosa Damascena oil improved sexual dysfunction and happiness among male opioid addicts while under substitution treatment with methadone.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Antipsychotic Effects of Cannabidiol

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1 ◽  
Author(s):  
F.M. Leweke ◽  
D. Koethe ◽  
F. Pahlisch ◽  
D. Schreiber ◽  
C.W. Gerth ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Paranoid Schizophrenia ◽  
Treatment Strategies ◽  
Endocannabinoid System ◽  
Psychotic Symptoms ◽  
Controlled Clinical Trial ◽  
Antipsychotic Treatment ◽  
Double Blind ◽  
Acute Schizophrenia

Background:In contrast to delta-9-tetrahydrocannabinol, the phytocannabinoid cannabidiol does not exert psychotomimetic effects. Cannabidiol was suggested a re-uptake inhibitor of anandamide and potential antipsychotic properties have been hypothesized for it. We therefore performed a clinical trial to investigate thesis hypothesis and to clarify the underlying link to the neurobiology of schizophrenia.Methods:We performed an explorative, 4-week, double-blind, controlled clinical trial on the effects of purified cannabidiol in acute schizophrenia compared to the antipsychotic amisulpride. The antipsychotic properties of both drugs were the primary target of the study. Furthermore, side-effects and anxiolytic capabilities of both treatments were investigated.Results:42 patients fulfilling DSM-IV criteria of acute paranoid schizophrenia participated in the study. Both treatments were associated with a significant decrease of psychotic symptoms after 2 and 4 weeks as assessed by BPRS and PANSS. However, there was no statistical difference between both treatment groups. In contrast, cannabidiol induced significantly less side effects (EPS, increase in prolactin, weight gain) when compared to amisulpride.Conclusions:Cannabidiol revealed substantial antipsychotic properties in acute schizophrenia. This is in line with our suggestion of an adaptive role of the endocannabinoid system in paranoid schizophrenia, and raises further evidence that this adaptive mechanism may represent a valuable target for antipsychotic treatment strategies.The Stanley Medical Research Institute (00-093 to FML) and the Koeln Fortune Program (107/2000 + 101/2001 to FML) funded this study.

Maprotiline (Ludiomil) and Imipramine in Depressed In-Patients: A Controlled Study

1975 ◽  
Vol 3 (6) ◽  
pp. 413-416 ◽  
Author(s):  
W Rieger ◽  
K Rickels ◽  
N Norstad ◽  
J Johnson
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Clinical Efficacy ◽  
Hospitalized Patients ◽  
Strong Tendency ◽  
Controlled Study ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Double Blind ◽  
Randomized Controlled

In this double-blind, randomized, controlled clinical trial of maprotiline ( Ludiomil) against imipramine involving twenty-five newly admitted hospitalized patients, a strong tendency in favour of maprotiline over imipramine emerged. Improvement occurred faster and also at treatment end-point the trend in favour of maprotiline was still to be seen. The slight superiority in clinical efficacy of maprotiline over imipramine was present in both physician and patient measures. Incidences of side-effects were slightly lower for maprotiline than for imipramine.

scholarly journals A clinical efficacy of 30% ethenolic extract of Indian propolis and Recaldent TM in management of dentinal hypersensitivity: A comparative randomized clinical trial

2013 ◽  
Vol 07 (04) ◽  
pp. 461-468 ◽  
Author(s):  
Nilesh Arjun Torwane ◽  
Sudhir Hongal ◽  
Pankaj Goel ◽  
B. R. Chandrashekar ◽  
Manish Jain ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Rating Scale ◽  
Intervention Group ◽  
Controlled Clinical Trial ◽  
Sterile Water ◽  
Double Blind ◽  
Treatment Groups ◽  
Casein Phosphopeptide ◽  
Group B ◽  
Dentinal Hypersensitivity

ABSTRACT Objective: The aim of this study is to evaluate the efficacy of 30% ethenolic extract of Indian propolis compared with Recaldent TM (casein phosphopeptide-amorphous calcium phosphate) in reduction of dentinals hypersensitivity, a randomized, double-blind, split mouth, controlled clinical trial was conducted among the patients residing in Central Jail. Materials and Methods: A sample of 73 teeth from 13 patients having at least three teeth with dentinal hypersensitivity (DH) were randomly allocated into three treatment groups: Group A: 30% ethenolic extract of Indian propolis, Group B: Recaldent TM , Group C: Sterile water. Verbal rating scale was used to record the degree of hypersensitivity based on patient′s response to tactile and air blast stimuli. The baseline scores were obtained. Each intervention group received applications of their respective agents consecutively on 1 st , 7 th , 14 th , and 21 st day. After each application the scores were recorded. Results: Both the 30% Indian propolis and Recaldent TM showed significant reduction in DH. Conclusions: Recaldent TM was found to be significantly better in reducing the DH compared to propolis and sterile water (P < 0.01).

Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: a randomized double-blind controlled clinical trial.

1985 ◽  
Vol 3 (8) ◽  
pp. 1133-1135 ◽  
Author(s):  
J T D'Olimpio ◽  
F Camacho ◽  
P Chandra ◽  
M Lesser ◽  
M Maldonado ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Median Duration ◽  
Treated Group ◽  
Controlled Clinical Trial ◽  
High Dose ◽  
Double Blind ◽  
Antiemetic Effect ◽  
High Dose Dexamethasone ◽  
Number Of Patients ◽  
Gi Toxicity

The antiemetic effect of short courses of high-dose dexamethasone was compared with that of placebo in 64 patients receiving cisplatin-based cancer chemotherapy, in a double-blind randomized clinical trial. All patients were receiving cisplatin for the first time. Dexamethasone was given intravenously (IV) at a dose of 20 mg, two hours before and 3, 6, 9, and 12 hours after chemotherapy. Patients were crossed over to dexamethasone on the second cycle of chemotherapy if they experienced unacceptable gastrointestinal (GI) toxicity after initial treatment with placebo. Nine of 32 patients receiving dexamethasone and seven of 32 patients receiving placebo did not vomit. The median duration of nausea was significantly shorter (one-half hour) for the dexamethasone-treated group compared with that of placebo (31/2 hours). The number of patients who experienced unacceptable GI toxicity was significantly greater (53%) for the placebo patients than for those treated with dexamethasone (25%). Patients crossing over to dexamethasone after initially receiving placebo had a median duration of nausea of 11/2 hours and 24% did not vomit, results comparable to the first treatment group. We conclude that high-dose dexamethasone is only minimally effective as an antiemetic agent in patients receiving cisplatin-based chemotherapy.

A Comparative Study of Lactic Acid 10% and Ammonium Lactate 12% Lotion in the Treatment of Foot Xerosis

2002 ◽  
Vol 92 (3) ◽  
pp. 143-148 ◽  
Author(s):  
Maureen B. Jennings ◽  
Loretta Logan ◽  
Donna M. Alfieri ◽  
Charles F. Ross ◽  
Susan Goodwin ◽  
...  
Keyword(s):  
Clinical Trial ◽  
New York ◽  
Lactic Acid ◽  
Comparative Study ◽  
Clinical Assessment ◽  
Double Blind ◽  
Treatment Groups ◽  
Baseline Visit ◽  
Ammonium Lactate ◽  
Significant Difference

Xerotic skin is a pattern of reaction to a variety of disorders that have abnormalities of desquamation in common. This double-blind, randomized clinical trial investigated the effect of Lactinol (Pedinol Pharmaceuticals, Farmingdale, New York) versus Lac-Hydrin 12% (Bristol-Myers Squibb, Princeton, New Jersey) lotion in mild to moderate foot xerosis. Clinical assessment of xerosis was performed at baseline visit, and the designated sites were evaluated at 2 and 4 weeks after treatment began. Of the 53 patients enrolled, 18 were excluded from analysis. Although both treatment groups had significantly improved xerosis scores after 2 and 4 weeks of treatment, no statistically significant difference was observed. Of the 44% of patients who did express a preference, 72% preferred Lactinol, which may account for the 20% increase in its overall use in the study. (J Am Podiatr Med Assoc 92(3): 143-148, 2002)

scholarly journals The effect of blue and pink lotus flower extract on acne vulgaris: A randomized double-blind clinical trial

2021 ◽  
Author(s):  
Anna Gordon
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Treatment Group ◽  
Side Effect ◽  
Acne Vulgaris ◽  
Treated Group ◽  
Small Sample ◽  
Double Blind ◽  
Flower Extract ◽  
Lotus Flower

Background: Acne vulgaris is one of the leading ubiquitous diseases around the world. It is a multifactorial disease which does not threaten life but has serious psychological effects on patients. Patients with moderate to severe acne have been suggested to have poor body image, poor self-esteem, and social isolation and activity constraints. Increased levels of anxiety, anger, depression and frustration are also observed in patients with acne as part of the emotional impact. Research gap: More research onanti-acne treatmentsis necessary for two reasons. First, the prevalence of acne incidence is high and the effect on the quality of life is profound. Second, there is, according to the numerous studies, a lack of ant-acne treatments that have less side effect. The use ofmedicinal plants and particularly blue and pink lotus flower extract, with its autoinflammatory effect, could be promising. The blue and pink lotus flower extract is suggested to reduces the activity of sebum overproduction and helps to balance sebum secretion. Objective:The objective of this study was to examine the medical efficacy ofblue and pink lotus flower extract in acne vulgaris. Method:In a randomized double-blind controlled clinical trial, 42 patients (21 patients in treatment and 21 in placebo group) were randomly received Nymphaea Caerulea Flower Extract, Nelumbo Nucifera Flower and placebo extract, twice daily for 1 month. We recorded he Investigator's Global Assessment (IGA) grading score for each participant. In addition, we evaluated the Acne disability index (ADI) utilizing a standard questionnaire filled out by the participants at the beginning and at the end of the study. Results:The results indicated a 76% mean reduction in the IGA score on the treated group. The mean reduction in the vehicle-treated group, on the other hand, was 4.2%. We also found that the number of comedones, papules, and pustules significantly reduced in the treatment group after 30 days. Additionally, the Acne disability index (ADI) score decreased by 65.01 percent in treatment group, and only 5.6 percent in the placebo group. The current study could not discover any significant side effect in both groups. Conclusion:The blue and pink lotus flower extract had significant effects on improving the symptoms of acnevulgaris. The results of this study, because of the small sample size, should however be interpreted with caution. The future study on the medical efficacy of the mentioned extract should examine with larger samples.

Sign in / Sign up

Export Citation Format

Share Document